Search - tctmd.com

Displaying 361 - 380 of 764

Sort: Relevancy | Date

Presentation TCT 2014

TCT 15: Abluminal Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent in Patients Undergoing Primary Percutaneous Coronary Intervention: 3-Year Follow-up From the COMPARE II Trial

Presenter: John M. Lasala, Stuart J. Pocock, Georgios Vlachojannis, MD

September 16, 2014

Presentation TCT 2014

TCT 576: Primary Endpoint Results From the PROMUS Element Plus US Postapproval Study (PE-Plus PAS): 1-Year Outcomes in Real-World Patients Treated with a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent

Presenter: John M. Lasala, Stuart J. Pocock, David E. Kandzari

September 16, 2014

Presentation TCT 2014

EVERBIO II: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting and Biolimus-Eluting Metallic Stents in Patients with Coronary Artery Disease

Presenter: Mitchell W. Krucoff, Giulio G. Stefanini, Stephane Cook

September 16, 2014

Presentation TCT 2014

Comparison of Novel Zotarolimus-Eluting Cobalt-Chromium Stents and Everolimus-Eluting Platinum-Chromium Stents in Patients of the Randomized DUTCH PEERS Trial Presenting with___

Presenter: Marije L?wik

September 16, 2014

Presentation TCT 2014

Analysis of Quality of Life Decrements Associated with Changes in Angina Status in the ABSORB II Trial: First Randomized Comparison Between the Absorb? Everolimus Eluting___

Presenter: Bernard Chevalier

September 16, 2014

Presentation TCT 2014

Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent in patients undergoing primary percutaneous coronary intervention: 3 Year___

Presenter: Georgios Vlachojannis

September 16, 2014

Presentation TCT 2014

Long-term Clinical Outcomes in Real-World Patients with Acute Myocardial Infarction Receiving XIENCE V® Everolimus-Eluting Stents: Four-Year Results from the XIENCE V USA Study_

Presenter: Krishnankutty Sudhir

September 16, 2014

Presentation TCT 2014

Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing primary percutaneous coronary intervention: 5 year follow-up from the COMPARE I___

Presenter: Georgios Vlachojannis

September 16, 2014

Presentation TCT 2014

ABSORB Cohort B Trial: Five Year Angiographic Results Of The ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold_

Presenter: Bernard De Bruyne

September 16, 2014

News Industry News

New All-Comers Study Compares Efficacy of Bioresorbable Vascular Scaffold to Best-in-Class Drug Eluting Stents

September 16, 2014

Presentation TCT 2014

Platinum-Chromium Platform with Reduced Polymer Load and Rapid Bioabsorption: Everolimus-Eluting SYNERGY Program Update

Presenter: Alexandre Abizaid, Pieter C. Smits, Robert J. Gil, Ian T. Meredith

September 15, 2014

Presentation TCT 2014

TCT 584: Abluminal Biodegradable Polymer, Biolimus-Eluting Stent Versus Durable Polymer, Everolimus-Eluting Stent: 3-Year Follow-up from the COMPARE II Trial

Presenter: Alexandre Abizaid, Pieter C. Smits, Robert J. Gil

September 15, 2014

News Conference News TCT 2014

Keynote Address Focuses on Newer DES, Problematic Subgroups

September 15, 2014

News Conference News TCT 2014

EES Decrease Restenosis, TVR vs. BMS in Non-STEMI

September 15, 2014

News Industry News

Abbott Initiates ABSORB IV Trial to Evaluate Quality of Life and Cost Savings of Dissolving Heart Device

September 15, 2014

Presentation TCT 2014

TCT 642: Stent Thrombosis Rates with an Abluminal Biodegradable Polymer, Biolimus-Eluting Stent Versus a Durable Polymer, Everolimus-Eluting Stent in Patients Undergoing Percutaneous Coronary Intervention: 3-Year Follow-up from the COMPARE II Trial

Presenter: Pieter C. Smits

September 14, 2014

Presentation TCT 2014

TCT 641: Improved Safety and Reduction in Stent Thrombosis After Everolimus-Eluting Stents Versus Sirolimus-Eluting Stents in Patients with Coronary Artery Disease: SORT-OUT IV 5-Year Results

Presenter: Donald Cutlip, Manel Sabate, Elvin Kedhi, Lisette Okkels Jensen

September 14, 2014

Presentation TCT 2014

RIBS IV: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients with Coronary In-Stent Restenosis of Drug-Eluting Stents

Presenter: Gregg W. Stone, Pieter C. Smits, Fernando Alfonso

September 14, 2014

Presentation TCT 2014

ABSORB II: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus an Everolimus-Eluting Metallic Stent in Patients with Coronary Artery Disease

Presenter: Gregg W. Stone, Pieter C. Smits, Patrick W. Serruys

September 14, 2014

News Conference News TCT 2014

RIBS IV: EES Superior to DEB in Patients with In-Stent Restenosis

September 14, 2014

Advertisement

TCT 15: Abluminal Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent in Patients Undergoing Primary Percutaneous Coronary Intervention: 3-Year Follow-up From the COMPARE II Trial

TCT 576: Primary Endpoint Results From the PROMUS Element Plus US Postapproval Study (PE-Plus PAS): 1-Year Outcomes in Real-World Patients Treated with a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent

EVERBIO II: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting and Biolimus-Eluting Metallic Stents in Patients with Coronary Artery Disease

Comparison of Novel Zotarolimus-Eluting Cobalt-Chromium Stents and Everolimus-Eluting Platinum-Chromium Stents in Patients of the Randomized DUTCH PEERS Trial Presenting with___

Analysis of Quality of Life Decrements Associated with Changes in Angina Status in the ABSORB II Trial: First Randomized Comparison Between the Absorb? Everolimus Eluting___

Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent in patients undergoing primary percutaneous coronary intervention: 3 Year___

Long-term Clinical Outcomes in Real-World Patients with Acute Myocardial Infarction Receiving XIENCE V® Everolimus-Eluting Stents: Four-Year Results from the XIENCE V USA Study_

Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing primary percutaneous coronary intervention: 5 year follow-up from the COMPARE I___

ABSORB Cohort B Trial: Five Year Angiographic Results Of The ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold_

New All-Comers Study Compares Efficacy of Bioresorbable Vascular Scaffold to Best-in-Class Drug Eluting Stents

Platinum-Chromium Platform with Reduced Polymer Load and Rapid Bioabsorption: Everolimus-Eluting SYNERGY Program Update

TCT 584: Abluminal Biodegradable Polymer, Biolimus-Eluting Stent Versus Durable Polymer, Everolimus-Eluting Stent: 3-Year Follow-up from the COMPARE II Trial

Keynote Address Focuses on Newer DES, Problematic Subgroups

EES Decrease Restenosis, TVR vs. BMS in Non-STEMI

Abbott Initiates ABSORB IV Trial to Evaluate Quality of Life and Cost Savings of Dissolving Heart Device

TCT 642: Stent Thrombosis Rates with an Abluminal Biodegradable Polymer, Biolimus-Eluting Stent Versus a Durable Polymer, Everolimus-Eluting Stent in Patients Undergoing Percutaneous Coronary Intervention: 3-Year Follow-up from the COMPARE II Trial

TCT 641: Improved Safety and Reduction in Stent Thrombosis After Everolimus-Eluting Stents Versus Sirolimus-Eluting Stents in Patients with Coronary Artery Disease: SORT-OUT IV 5-Year Results

RIBS IV: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients with Coronary In-Stent Restenosis of Drug-Eluting Stents

ABSORB II: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus an Everolimus-Eluting Metallic Stent in Patients with Coronary Artery Disease

RIBS IV: EES Superior to DEB in Patients with In-Stent Restenosis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content